For pricing in USD please contact us

Recombinant Multidrug Resistance ABC Transporter ATP-Binding - 10 µg

Recombinant Multidrug Resistance ABC Transporter ATP-Binding - 10 µg

Regular price
$314.85 CAD
Regular price
Sale price
$314.85 CAD
Unit price
per 
Availability
Sold out

BmrA transporters are powerful therapeutic targets for multi-drug resistance studies, ideal for therapeutic indications such as bacterial resistance to antibiotics.

CALIXAR’s BmrA transporter (Bacilus subtilis multidrug resistance ABC transporter ATP-binding Protein) is an efflux protein and ABC transporter that acts as a mechanical pump for ATP dependent drug efflux. This unique characteristic makes BmrA transporters a powerful therapeutic target for multi-drug resistance studies.

CALIXAR’s BmrA Transporters aid in the exploration, improvement, validation of novel molecules and therapeutic antibodies. Our BmrA transporters are excellent for therapeutic indications such as bacterial resistance to antibiotics.

 

Target name: Multidrug resistance ABC transporter ATP-binding/permease protein (BmrA)

Catalogue number: PP3

Class: Multidrug resistance ABC transporter

Sequence: Full-length, wildtype sequence, with a N-terminus 6xHis-tag.

Affinity Tag​: His-tag (N-terminal)

Origin: Bacillus subtilis (strain 168)

Theor. MW: 64.5 kDa

Accession #: O06967 (UniProt)​

Shipment temperature: Dry Ice

Storage conditions: Store at -80°C​

 

Expression system: Escherichia coli ( BL21C43)

Purity: >90%

Purification: Immobilized Metal Affinity Chromatography

Activity: Confirmed by ATPase activity assay

Concentration​: Up to 5mg/ml

Sample buffer: 50mM Tris-Cl pH 8.0, 100 mM NaCl, 0.01% DDM, 10%glycerol

Available quantity: From 10µg up to mg scale

 

  

CALIXAR utilizes a unique & custom method

CALIXAR’s BmrA transporters expedite reliable fragment-based drug design (FBDD), structure-based medication discovery (SBDD) and antibody development against this specific target.

Unlike CALIXAR’s BmrA transporters, other alternative approaches result in a BmrA transporter that becomes mutated and truncated.

As with all transporters, BmrA transporters are unpredictable targets and are difficult to produce natively without particular technology. Traditionally, BmrA transporters were often developed in a solution that naturally could not be pure, nor native (truncated, mutated), and consequently are moderately unstable.

Thanks to CALIXAR’s expertise, we are able to deliver BmrA transporters that maintain the structure and function of the target. Our BmrA transporters are pure, native, unaltered and stable.

CALIXAR has the capacity to provide high quality, native, wild-type, unaltered, unmutated and untruncated targets for antibody development and pharmaceutical discovery projects. They are unparalleled in the market and at the vanguard of Membrane Protein technology.

 

CALIXAR’s BmrA TransporterS ARE the original native full-length and functional target on the market. Other existing BmrA targets are either mutated or truncated. Our BmrA transporter protein is produced in a prokaryotic system.

 

CALIXAR’s BmrA transporter are high-quality membrane proteins utilized for (bio)drug discovery and are adapted for use in pharmaceutical companies, biotechnology companies, as well as for academic teams that are involved in the life science domains.

 

  • Antibodies (including nanobodies, scaffold proteins, aptamers)
  • Small molecules
  • 3D Structures (classical X-ray or XFEL, Cryo-EM, NMR)
  • Drug discovery (Screening: HTS, FBDD, SBDD; Hit and lead validation)
  • Antibody discovery (Immunization and display technologies)
  • Clinical stage (drug validation on reliable native BmrA)​

References

ANALYTICAL BIOCHEMISTRY

Novel systematic detergent

Desuzinges Mandon E. et al. 2017 

PLOS ONE

Structuring detergents for extracting and stabilizing functional membrane proteins.

Matar-Merheb R. et al. 2011